An early-biomarker algorithm predicts lethal graft-versus-host disease and survival

BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to the onset of GVHD symptoms. METHODS. Patient blood samples on day 7 after HCT were obtained from a multicenter set...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Hartwell, Matthew J., Özbek, Umut, Holler, Ernst, Renteria, Anne S., Major-Monfried, Hannah, Reddy, Pavan, Aziz, Mina, Hogan, William J., Ayuk, Francis, Efebera, Yvonne A., Hexner, Elizabeth O., Bunworasate, Udomsak, Qayed, Muna, Ordemann, Rainer, Wölfl, Matthias, Mielke, Stephan, Pawarode, Attaphol, Chen, Yi-Bin, Devine, Steven, Harris, Andrew C., Jagasia, Madan, Kitko, Carrie L., Litzow, Mark R., Kröger, Nicolaus, Locatelli, Franco, Morales, George, Nakamura, Ryotaro, Reshef, Ran, Rösler, Wolf, Weber, Daniela, Wudhikarn, Kitsada, Yanik, Gregory A., Levine, John E., Ferrara, James L.M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2017
Aiheet:
Clinical Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291735/
https://ncbi.nlm.nih.gov/pubmed/28194439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89798
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia